Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

